Overcoming the Challenges of Multi-Target Drug Discovery
Drugs that act at more than one target can provide a more effective way of treating complex diseases than the use of target-selective agents. This one-day conference will highlight the relevance of this field to drug discovery, include some successful dual ligand case histories, the lessons learned from past projects and will look into the crystal ball to predict how this field may develop in the years ahead.

Programme

09.30 Registration and Coffee

Chair: Andrew Payne

10.00 Mark Millan (Servier): Multi-target strategies for improving the treatment of CNS disorders: rationale and application

10.45 Rolf Feenstra (Solvay): Design of molecules combining D2 receptor affinity with 5HT1A receptor affinity or SERT inhibition for the development of potential atypical antipsychotics

11.30 Christophe Genicot (UCB Pharma): Design of dual acting ligands (Atarax-SSRI, NK1-SSRI and M3-PDE4): challenges and opportunities

12.15 Lunch

Chair: Karl Gibson

13.15 Florian Wakenhut (Pfizer): Discovery of PF-184298, a dual serotonin/noradrenalin reuptake inhibitor

14.00 Wolfgang Sippl and Jean-Marie Contreras (University Halle): Design Strategies for Identical and Non-Identical Twin Drugs

14.45 Tea

15.15 Karen Lackey (GSK): Discovery of Tykerb: lessons learned in designing a kinase inhibition profile

16.00 Andrew Hopkins (Pfizer): Network Therapies: the next paradigm in drug discovery?

16.45 Close of meeting